Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

News
1 - 10of about 50 News
1 - 10of about 50 News
September 08, 2022
Not intended for U.S. and UK Media
Aflibercept 8 mg first to achieve extended injection intervals of 16 weeks in up to 89% of patients
READ MORE
September 02, 2022
Not intended for U.S. and UK Media
Kerendia™ (finerenone) receives updated label in the U.S. to include findings from Phase III FIGARO-DKD cardiovascular outcomes study
READ MORE
September 01, 2022
Kimberly Mathisen appointed to the Supervisory Board of Bayer AG
READ MORE
August 28, 2022
Not intended for U.S. and UK Media
Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian
READ MORE
August 12, 2022
Bayer statement on the decision in the BASF arbitration proceedings
READ MORE
August 11, 2022
Bayer Showcases Leadership in Breakthrough Innovations and Sustainable, Tailored Solutions to Meet Global Challenges in Agriculture
READ MORE
August 08, 2022
Not intended for U.S. and UK Media
U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
READ MORE
August 04, 2022
Second quarter of 2022
Bayer: Strong growth, outlook raised
READ MORE
August 01, 2022
Bayer expands existing investment to acquire majority share in sustainable lower carbon oilseed producer CoverCress Inc.
READ MORE
July 14, 2022
Bayer to sell men’s health product Nebido™ to Grünenthal
READ MORE
1 - 10of about 50 News
1 - 10of about 50 News

 

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases
Discover Bayer's Latest Ad-Hoc Releases
read more